Table 4.
Effect measure modification for mean change in weight from baseline to 12-months.
| Stratification variables | Mean change in weight (kg) |
||
|---|---|---|---|
| Efavirenz mean (95% CI) |
Dolutegravir mean (95% CI) |
Crude mean change between columns (95% CI) |
|
| Original analysis (crude) | 1.45 (SD 5.24) | 2.79 (SD 6.66) | 1.34 (0.75, 1.93) |
| Sex | |||
| Male | 0.97 (0.39, 1.56)a | 2.42 (1.84, 3.00) | 1.45 (0.61, 2.29) |
| Female | 1.95 (1.36, 2.55) | 3.19 (2.59, 3.79) | 1.24 (0.41, 2.06) |
| Age (years) | |||
| 16–24.9 | 1.45 (0.35, 2.55) | 1.72 (0.56, 2.87) | 0.27 (−1.73, 2.27) |
| 25–29.9 | 2.50 (0.88, 4.13) | 2.68 (1.10, 4.26) | 0.18 (−1.96, 2.31) |
| 30–39.9 | 1.84 (1.14, 2.54) | 2.61 (1.89, 3.33) | 0.77 (−0.14, 1.68) |
| 40–49.9 | 1.35 (0.59, 2.12) | 3.30 (2.56, 4.03) | 1.94 (0.85, 3.03) |
| ≥50 | 0.24 (−0.86, 1.33)a | 3.11 (2.02, 4.21) | 2.88 (1.42, 4.34) |
| CD4 count (cells/mm3) (%) | |||
| <200 | 2.32 (0.57, 3.97)a | 3.00 (1.52, 4.48) | 0.28 (−1.76, 3.12) |
| 200–299 | 1.69 (0.60, 2.79) | 3.26 (2.19, 4.33) | 1.57 (0.10, 3.03) |
| 300–399 | 2.04 (1.04, 3.05) | 2.74 (1.73, 3.75) | 0.70 (−0.66, 2.06) |
| 400–499 | 1.45 (0.41, 2.49) | 2.03 (0.97, 3.10) | 0.59 (−1.50, 2.67) |
| ≥500 | 1.03 (0.42, 1.65) | 2.88 (2.25, 3.50) | 1.84 (1.10, 2.86) |
| Viral load suppression (<1000 copies/mL) | |||
| No | 3.51 (−0.93, 7.96)a | 0.88 (−3.92, 5.68) | −2.63 (−8.73, 3.47) |
| Yes | 1.43 (1.01, 1.85) | 2.81 (2.39, 3.23) | 1.37 (0.78, 1.97) |
| Time on ART (months) | |||
| 0–11.9 | 4.15 (2.92, 5.38) | 4.60 (3.36, 5.83) | 0.44 (−1.50, 2.40) |
| 12–23.9 | 2.07 (1.16, 2.97) | 2.40 (1.44, 3.36) | 0.33 (−0.98, 1.64) |
| 24.0–35.9 | 0.23 (−0.94, 1.39) | 3.15 (1.98, 4.32) | 2.92 (1.57, 4.27) |
| 36.0–47.9 | 1.15 (−0.23, 2.53) | 2.60 (1.28, 3.93) | 1.45 (−0.24, 3.15) |
| 48–59.9 | 0.20 (−1.22, 1.62) | 3.00 (1.61, 4.38) | 2.80 (1.06, 4.54) |
| ≥60 | 1.06 (0.39, 1.74)a | 2.35 (1.69, 3.01) | 1.28 (0.27, 2.30) |
| Body Mass Index (kg/m2) | |||
| <18.5 | −0.55 (−3.06, 1.95)a | −0.50 (−2.80, 1.79) | 0.05 (−1.55, 1.64) |
| 18.5–24.9 | 0.11 (−0.57, 0.80) | 1.28 (0.60, 1.96) | 1.17 (0.31, 2.02) |
| 25–29.9 | 1.51 (0.73, 2.30) | 3.08 (2.31, 3.84) | 1.56 (0.53, 2.59) |
| ≥30.0 | 2.91 (2.22, 3.60) | 4.53 (3.82, 5.24) | 1.62 (0.45, 2.79) |
| Haemoglobin (ug/dL) (%) | |||
| <10.0 | −0.12 (−3.84, 3.60) | 0.81 (−2.23, 3.84) | 0.93 (−2.10, 3.95) |
| ≥10.0 | 1.47 (1.05, 1.89)a | 2.83 (2.41, 3.25) | 1.36 (0.76, 1.96) |
| Nucleoside reverse transcriptase inhibitor | |||
| lamivudine | 1.57 (1.08, 2.06)a | 3.07 (2.57, 3.55) | 1.50 (0.85, 2.14) |
| emtricitabine | 1.14 (0.35, 1.93) | 2.04 (1.24, 2.85) | 0.90 (−0.42, 2.22) |
| Hypertension (%) | |||
| No | 1.68 (1.23, 2.14)a | 2.85 (2.39, 3.30) | 1.17 (0.53,1.80) |
| Yes | 0.25 (−0.79, 1.29) | 2.51 (1.49, 3.53) | 2.26 (0.68, 3.85) |
a
Reference group.